Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.36 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.35 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.34 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.34 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.34 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TLR2 | O60603 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16189800 | 0.91 | DNM1 (0.38) | TSHRDNM1LPAR1LPAR3LPAR2 | |
| SCHEMBL1776900 | 0.85 | DNM1 (0.42) | TSHRDNM1LPAR1LPAR3LPAR2 | |
| SCHEMBL15624089 | 0.84 | TSHR (0.41) | TSHRDNM1PLA2G2CALDH1A1CNR1 | |
| SCHEMBL13239753 | 0.82 | LPAR1 (0.36) | DNM1LPAR1LPAR3LPAR2PLA2G2C | |
| SCHEMBL16391359 | 0.81 | CNR2 (0.49) | TSHRDNM1LPAR1LPAR3LPAR2 | |
| SCHEMBL1781072 | 0.79 | DNM1 (0.50) | TSHRDNM1LPAR1LPAR3LPAR2 | |
| SCHEMBL10791875 | 0.79 | TSHR (0.33) | TSHRDNM1PLA2G2CALDH1A1HPGD | |
| SCHEMBL9289205 | 0.79 | TSHR (0.36) | TSHRDNM1PLA2G2CALDH1A1CNR1 | |
| SCHEMBL13239759 | 0.78 | TSHR (0.37) | TSHRLPAR1LPAR3LPAR2PLA2G2C | |
| SCHEMBL13239247 | 0.78 | TSHR (0.37) | TSHRLPAR1LPAR3LPAR2PLA2G2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8350062-B2 | Synthesis and anticancer activity of new actin-targeting small-molecule agents | THE UNIVERSITY OF CHICAGO (US) | 2013-01-08 | — | — | US | disclosed |
| US-20100217019-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF NEW ACTIN-TARGETING SMALL-MOLECULE AGENTS | THE UNIVERSITY OF CHICAGO | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100217019-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF NEW ACTIN-TARGETING SMALL-MOLECULE AGENTS | ACTR2, ACTR3, ACTB | TSHR 4110/4885DNM1 204/4885LPAR1 3008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.